GlassScriptPhysician profile
Douglas C Moody
NPI 1427040450
$5,475.44
in general payments reported to CMS, 2019-2025
43 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $456 · 2021: $889 · 2022: $1,172 · 2023: $949 · 2024: $657 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $833.66 | 2019-2025 | |
| Abbvie INC. | $695.81 | 2019-2025 | |
| Novo Nordisk INC | $608.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $329.97 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $283.89 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Amgen INC. | $241.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $238.71 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $238.40 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.25 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $156.97 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $153.08 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $150.97 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $135.19 | 2019-2022 | |
| Daiichi Sankyo INC. | $103.11 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.31 | 2019-2025 | Xifaxan |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Moody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.